Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPeptide Group AGPLYGF +26.56%60 EV-to-OCF is 30.56 as of Aug. 20, 2026, which is 8% above its 10-year median of 28.33. GuruFocus rates PLYGF with a GF Score™ of 60/100 and a GF Value™ of $31.63 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 79.6% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PolyPeptide Group AG's Enterprise Value is $1,884.6 Mil.
PolyPeptide Group AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $61.7 Mil. Therefore, PolyPeptide Group AG's EV-to-OCF for today is 30.56.
The historical rank and industry rank for PolyPeptide Group AG's EV-to-OCF or its related term are showing as below:
PLYGF'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.05 Med: 28.33 Max: 171.59
Current: 31.05
During the past 8 years, the highest EV-to-OCF of PolyPeptide Group AG was 171.59. The lowest was 6.05. And the median was 28.33.
PLYGF's EV-to-OCF is ranked worse than 79.6% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.86
vs PLYGF: 31.05
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PolyPeptide Group AG (OTCPK:PLYGF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PolyPeptide Group AG's PE Ratio (TTM) for today is calculated as:
PolyPeptide Group AG's share price for today is $54.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PolyPeptide Group AG EV-to-OCF Related Terms
PolyPeptide Group AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's EV-to-OCF falls into.
PolyPeptide Group AG's current Enterprise Value is $1,884.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $61.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a EV-to-OCF of 30.56 as of Aug. 20, 2026. This is near median its historical median of 28.33. Over the past decade, PolyPeptide Group AG's EV-to-OCF has ranged from 6.05 to 171.59. According to the industry distribution chart, PolyPeptide Group AG ranks #800 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 79.6%.
Is PolyPeptide Group AG's EV-to-OCF too high?
PolyPeptide Group AG's current EV-to-OCF of 30.56 is near median its 10-year median of 28.33. Over the past 10 years, this metric has ranged from a low of 6.05 to a high of 171.59. The Drug Manufacturers industry median EV-to-OCF is 10.86. PolyPeptide Group AG's value of 30.56 is 181.4% above this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #800 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PolyPeptide Group AG has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #800 out of 1005 companies for EV-to-OCF. This places PolyPeptide Group AG in the lower half of its industry. The industry median EV-to-OCF is 10.86. PolyPeptide Group AG's value of 30.56 is 181.4% above this benchmark. Historically, PolyPeptide Group AG's own EV-to-OCF has ranged from 6.05 to 171.59 over the past decade. While the company's 10-year median is 28.33 vs. the industry median of 10.86, PolyPeptide Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.86, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current EV-to-OCF of 30.56 is 181.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current EV-to-OCF is 30.56, which is near median its own 10-year median of 28.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.63, compared to a current price of $54.42 — trading 72.1% above its estimated fair value. The current EV-to-OCF is 30.56, which is near median its 10-year median of 28.33 and 181.4% above the Drug Manufacturers industry median of 10.86. PolyPeptide Group AG's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current EV-to-OCF is 30.56 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $54.42 is trading 72.1% above its estimated GF Value™ of $31.63.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for PLYGF:
EV-to-OCF: 30.56 (near median its 10-year median of 28.33)
GF Value™: $31.63 vs. price of $54.42 (72.1% above fair value)
Industry Position: 181.4% above the Drug Manufacturers median (#800 of 1005)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
60GF Score
Get the complete analysis for PLYGF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
